These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2678304)

  • 21. Blood pressure and aortic elastic properties--verapamil SR/trandolapril compared to a metoprolol/hydrochlorothiazide combination therapy.
    Breithaupt-Grögler K; Gerhardt G; Lehmann G; Notter T; Belz GG
    Int J Clin Pharmacol Ther; 1998 Aug; 36(8):425-31. PubMed ID: 9726695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketanserin, hypertension, and chronic alcoholism: double-blind study in forty patients.
    de Lorenzo A; Ceccanti M; Assogna G; Romeo M; Cavaleri G; Attilia ML
    Int J Clin Pharmacol Res; 1988; 8(5):321-5. PubMed ID: 3068159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin.
    Vanhoutte P; Amery A; Birkenhäger W; Breckenridge A; Bühler F; Distler A; Dormandy J; Doyle A; Frohlich E; Hansson L
    Hypertension; 1988 Feb; 11(2):111-33. PubMed ID: 3277910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antihypertensive mechanism of ketanserin in postoperative hypertension after cardiopulmonary bypass.
    Anger C; Carter JA; Prys-Roberts C
    Anesth Analg; 1988 Feb; 67(2):99-106. PubMed ID: 3277483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ketanserin: a novel cardiovascular drug.
    Symoens J
    Blood Coagul Fibrinolysis; 1990 Jun; 1(2):219-24. PubMed ID: 2130934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of anti-hypertensive treatment on plasma lipids and lipoproteins (author's transl)].
    Sauvanet JP; Rouffy J
    Pathol Biol (Paris); 1981 Sep; 29(7):435-40. PubMed ID: 6117048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.
    Xie F; Petitti DB; Chen W
    Am J Hypertens; 2005 Apr; 18(4 Pt 1):464-9. PubMed ID: 15831354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs.
    Novo S; Alaimo G; Abrignani MG; Giordano U; Avellone G; Pinto A; Adamo L; Cutietta A; Indovina A; Strano A
    Int J Clin Pharmacol Res; 1986; 6(3):199-211. PubMed ID: 2943685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Age and 5HT 2-receptor blockade with ketanserin in essential hypertension.
    Bühler FR; Amstein R
    Rev Port Cardiol; 1989 Sep; 8(9):621-4. PubMed ID: 2698721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specificity of the serotonergic antagonist ketanserin.
    Stott DJ; Robertson JI; Ball SG
    J Hypertens Suppl; 1985 Dec; 3(3):S191-3. PubMed ID: 2856702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum lipoproteins during treatment with antihypertensive drugs.
    Weidmann P; de Courten M; Ferrari P; Böhlen L
    J Cardiovasc Pharmacol; 1993; 22 Suppl 6():S98-105. PubMed ID: 7508069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in the chronic hypotensive mechanism of action of ketanserin in spontaneously hypertensive and Wistar-Kyoto rats.
    Balasubramaniam G; Lee HS; Mah SC
    J Hypertens; 1994 Jan; 12(1):7-14. PubMed ID: 8157947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of ketanserin and metoprolol in the treatment of essential hypertension.
    Sheps SG; Schirger A; Zachariah PK; Fisher LD; Spiekerman RE; Araas FJ; Collins JB; Agerter DC
    Arch Intern Med; 1987 Feb; 147(2):291-6. PubMed ID: 3545116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Serotonin antagonists for the treatment of hypertension].
    Bühler FR
    Schweiz Med Wochenschr; 1988 Sep; 118(36):1259-60. PubMed ID: 3175572
    [No Abstract]   [Full Text] [Related]  

  • 36. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
    Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
    Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of maternal ketanserin use on the circulation of the neonate: a prospective, observational study.
    Schaafstra L; van Roon EN; Morssink LP; de Vries NK
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):11-5. PubMed ID: 22349270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The renaissance of centrally acting antihypertensive drugs.
    van Zwieten PA
    J Hypertens Suppl; 1999 Aug; 17(3):S15-21. PubMed ID: 10489094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term antihypertensive efficacy of ketanserin plus chlorthalidone.
    Fasano ML; Soro S; Ferrara LA
    Drugs Exp Clin Res; 1989; 15(11-12):587-90. PubMed ID: 2700322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of ketanserin on blood pressure and platelets during cardiopulmonary bypass.
    Lichtenthal PR; Wade LD; Rossi EC
    Anesth Analg; 1987 Nov; 66(11):1151-4. PubMed ID: 3662060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.